Report highlights gap in CV patient education

17 September 2006

An international report authored by an alliance of leading heart disease, stroke and diabetes organizations across the world, warns that gaps in patient education on cardiovascular disease are holding back efforts to reduce deaths from heart attacks and strokes. The Look Closer Coalition, an initiative funded by leading French drugmaker Sanofi-Aventis and US major Bristol-Myers Squibb, highlights gaps in patient knowledge and physician tools to educate patients at high risk of CV disease about the underlying process that could lead to their death.

According to the report, failure by patients to understand the complex and holistic nature of their condition is hindering the management of heart attacks and strokes by physicians, which in turn leads to less patients complying with the preventive measures they recommend.

An international survey of over 800 physicians, called the Cardiovascular Health Outcomes: Issues in Communication and Education survey, commissioned specially for the report, revealed that doctors rarely discuss the underlying disease that causes a heart attack or stroke, with one in four almost never raising the subject in patient consultations. Instead, they focus on individual risk factors, such as high blood pressure and high cholesterol. In particular, they rarely discuss the leading cause of heart attacks and strokes: arterial blood clots.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight